Chemocentryx reported $26.01M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.06B 110M
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Amgen AMGN:US $ 1.23B 197M
AstraZeneca AZN:LN 3.06B 1.03B
Bayer BAYN:GR 3.94B 346M
Biogen BIIB:US $ 634.9M 153M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Chemocentryx CCXI:US $ 26.01M 2.72M
GlaxoSmithKline GSK:LN 2.68B 227M
Glaxosmithkline GSK:US 2.68B 227M
Johnson & Johnson JNJ:US $ 5.94B 1.22B
Macrogenics MGNX:US $ 16.25M 670K
Merk MRK:US $ 2.3B 518M
Mirati Therapeutics MRTX:US $ 53.95M 10.42M
Novartis NOVN:VX 3.5B 486M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Takeda 4502:JP 223.43B 7.65B
Teva Pharmaceutical TEVA:IT 819M 39M
YTE INCY:US $ 209.58M 16.62M